A Randomized, Double-masked, Placebo-controlled Exploratory Study to Evaluate Pharmacodynamics, Safety and Tolerability of Orally Administered BI 1026706 for 12 Weeks in Patients With Mild Visual Impairment Due to Center-involved Diabetic Macular Edema (DME)

Trial Profile

A Randomized, Double-masked, Placebo-controlled Exploratory Study to Evaluate Pharmacodynamics, Safety and Tolerability of Orally Administered BI 1026706 for 12 Weeks in Patients With Mild Visual Impairment Due to Center-involved Diabetic Macular Edema (DME)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs BI 1026706 (Primary)
  • Indications Diabetic macular oedema
  • Focus Pharmacodynamics
  • Sponsors Boehringer Ingelheim Pharma KG
  • Most Recent Events

    • 10 Oct 2017 Planned primary completion date changed from 6 Oct 2017 to 23 Oct 2017.
    • 21 Jul 2017 Planned End Date changed from 3 Nov 2017 to 23 Oct 2017.
    • 21 Jul 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top